Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma

Huilai Zhang, Ling Dong, Qingqing Chen, Lingzhe Kong, Bin Meng, Huaqing Wang, Kai Fu, Xi Wang, Qiang Pan-Hammarström, Ping Wang, Xianhuo Wang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chidamide (CS055) is a new and highly selective histone deacetylase inhibitor displaying significant single-agent activity in peripheral T-cell lymphoma (PTCL). But there is little known the synergistic effect between CS055 and chemotherapy. The purpose of this study is to explore the synergistic effect and molecular mechanisms of CS055 combination with Doxorubicin in PTCL cells. We found that CS055 showed dose- and time-dependent inhibition effects on PTCL cell. Meanwhile, the synergistic effect was significantly observed after combination treatment with lower drug-concentration of CS055 and Doxorubicin. Lower drug-concentration of CS055 induced weak apoptosis in PTCL cells, but combination treatment with CS055 and Doxorubicin promoted more significant apoptosis. Combination treatment with CS055 and Doxorubicin significantly changed mitochondrial membrane potential and H3 acetylated level, resulting in up-regulating DNA damage protein p-γH2AX and apoptosis proteins including cleaved-caspase-3, cleaved-caspase-9 and cleaved-PARP, and down-regulating anti-apoptosis protein Bcl-2. In a word, Doxorubicin could increase the CS055-induced inhibition effects on PTCL cells, suggesting that CS055 combination with Doxorubicin or Doxorubicin-based chemotherapy drugs might be a new therapy approach for PTCL patients.

Original languageEnglish (US)
Pages (from-to)29-35
Number of pages7
JournalLeukemia Research
Volume56
DOIs
StatePublished - May 1 2017

Fingerprint

Peripheral T-Cell Lymphoma
Histone Deacetylase Inhibitors
Doxorubicin
Apoptosis
Pharmaceutical Preparations
Drug Therapy
Proteins
Caspase 9
Mitochondrial Membrane Potential
Therapeutics
Caspase 3
DNA Damage

Keywords

  • Chidamide
  • Doxorubicin
  • PTCL
  • Synergistic antitumor effect

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma. / Zhang, Huilai; Dong, Ling; Chen, Qingqing; Kong, Lingzhe; Meng, Bin; Wang, Huaqing; Fu, Kai; Wang, Xi; Pan-Hammarström, Qiang; Wang, Ping; Wang, Xianhuo.

In: Leukemia Research, Vol. 56, 01.05.2017, p. 29-35.

Research output: Contribution to journalArticle

Zhang, H, Dong, L, Chen, Q, Kong, L, Meng, B, Wang, H, Fu, K, Wang, X, Pan-Hammarström, Q, Wang, P & Wang, X 2017, 'Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma', Leukemia Research, vol. 56, pp. 29-35. https://doi.org/10.1016/j.leukres.2017.01.025
Zhang, Huilai ; Dong, Ling ; Chen, Qingqing ; Kong, Lingzhe ; Meng, Bin ; Wang, Huaqing ; Fu, Kai ; Wang, Xi ; Pan-Hammarström, Qiang ; Wang, Ping ; Wang, Xianhuo. / Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma. In: Leukemia Research. 2017 ; Vol. 56. pp. 29-35.
@article{17fbc80e483a40dcac6167b83cb99fdc,
title = "Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma",
abstract = "Chidamide (CS055) is a new and highly selective histone deacetylase inhibitor displaying significant single-agent activity in peripheral T-cell lymphoma (PTCL). But there is little known the synergistic effect between CS055 and chemotherapy. The purpose of this study is to explore the synergistic effect and molecular mechanisms of CS055 combination with Doxorubicin in PTCL cells. We found that CS055 showed dose- and time-dependent inhibition effects on PTCL cell. Meanwhile, the synergistic effect was significantly observed after combination treatment with lower drug-concentration of CS055 and Doxorubicin. Lower drug-concentration of CS055 induced weak apoptosis in PTCL cells, but combination treatment with CS055 and Doxorubicin promoted more significant apoptosis. Combination treatment with CS055 and Doxorubicin significantly changed mitochondrial membrane potential and H3 acetylated level, resulting in up-regulating DNA damage protein p-γH2AX and apoptosis proteins including cleaved-caspase-3, cleaved-caspase-9 and cleaved-PARP, and down-regulating anti-apoptosis protein Bcl-2. In a word, Doxorubicin could increase the CS055-induced inhibition effects on PTCL cells, suggesting that CS055 combination with Doxorubicin or Doxorubicin-based chemotherapy drugs might be a new therapy approach for PTCL patients.",
keywords = "Chidamide, Doxorubicin, PTCL, Synergistic antitumor effect",
author = "Huilai Zhang and Ling Dong and Qingqing Chen and Lingzhe Kong and Bin Meng and Huaqing Wang and Kai Fu and Xi Wang and Qiang Pan-Hammarstr{\"o}m and Ping Wang and Xianhuo Wang",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.leukres.2017.01.025",
language = "English (US)",
volume = "56",
pages = "29--35",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma

AU - Zhang, Huilai

AU - Dong, Ling

AU - Chen, Qingqing

AU - Kong, Lingzhe

AU - Meng, Bin

AU - Wang, Huaqing

AU - Fu, Kai

AU - Wang, Xi

AU - Pan-Hammarström, Qiang

AU - Wang, Ping

AU - Wang, Xianhuo

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Chidamide (CS055) is a new and highly selective histone deacetylase inhibitor displaying significant single-agent activity in peripheral T-cell lymphoma (PTCL). But there is little known the synergistic effect between CS055 and chemotherapy. The purpose of this study is to explore the synergistic effect and molecular mechanisms of CS055 combination with Doxorubicin in PTCL cells. We found that CS055 showed dose- and time-dependent inhibition effects on PTCL cell. Meanwhile, the synergistic effect was significantly observed after combination treatment with lower drug-concentration of CS055 and Doxorubicin. Lower drug-concentration of CS055 induced weak apoptosis in PTCL cells, but combination treatment with CS055 and Doxorubicin promoted more significant apoptosis. Combination treatment with CS055 and Doxorubicin significantly changed mitochondrial membrane potential and H3 acetylated level, resulting in up-regulating DNA damage protein p-γH2AX and apoptosis proteins including cleaved-caspase-3, cleaved-caspase-9 and cleaved-PARP, and down-regulating anti-apoptosis protein Bcl-2. In a word, Doxorubicin could increase the CS055-induced inhibition effects on PTCL cells, suggesting that CS055 combination with Doxorubicin or Doxorubicin-based chemotherapy drugs might be a new therapy approach for PTCL patients.

AB - Chidamide (CS055) is a new and highly selective histone deacetylase inhibitor displaying significant single-agent activity in peripheral T-cell lymphoma (PTCL). But there is little known the synergistic effect between CS055 and chemotherapy. The purpose of this study is to explore the synergistic effect and molecular mechanisms of CS055 combination with Doxorubicin in PTCL cells. We found that CS055 showed dose- and time-dependent inhibition effects on PTCL cell. Meanwhile, the synergistic effect was significantly observed after combination treatment with lower drug-concentration of CS055 and Doxorubicin. Lower drug-concentration of CS055 induced weak apoptosis in PTCL cells, but combination treatment with CS055 and Doxorubicin promoted more significant apoptosis. Combination treatment with CS055 and Doxorubicin significantly changed mitochondrial membrane potential and H3 acetylated level, resulting in up-regulating DNA damage protein p-γH2AX and apoptosis proteins including cleaved-caspase-3, cleaved-caspase-9 and cleaved-PARP, and down-regulating anti-apoptosis protein Bcl-2. In a word, Doxorubicin could increase the CS055-induced inhibition effects on PTCL cells, suggesting that CS055 combination with Doxorubicin or Doxorubicin-based chemotherapy drugs might be a new therapy approach for PTCL patients.

KW - Chidamide

KW - Doxorubicin

KW - PTCL

KW - Synergistic antitumor effect

UR - http://www.scopus.com/inward/record.url?scp=85012273629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012273629&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2017.01.025

DO - 10.1016/j.leukres.2017.01.025

M3 - Article

C2 - 28171799

AN - SCOPUS:85012273629

VL - 56

SP - 29

EP - 35

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -